______
Supplementary Table1. Comparison of Progression to AIDS Outcomes among Cohorts of European-American Seroconverters in Early and Late Time Intervals
CD4200 / AIDS-1993 / AIDS-1987 / DeathHaplo- groupa / Time interval,
yearsb / n/events / RHc / (95% CI) / P / n/events / RHc / (95% CI) / P / Time interval,yearsb / n/events / RHc / (95% CI) / P / n/events / RHc / (95% CI) / P
MACS / R / 267/114 / 1.00 / – / – / 267/125 / 1.00 / – / – / 267/120 / 1.00 / – / – / 262/89 / 1.00 / – / –
F* / 30/10 / 0.74 / (0.40–1.50) / 0.46 / 30/11 / 0.77 / (0.41–1.42) / 0.40 / 31/11 / 0.73 / (0.40–1.36) / 0.33 / 30/6 / 0.55 / (0.24–1.26) / 0.16
I / 70/30 / 1.11 / (0.74–1.66) / 0.61 / 70/31 / 1.04 / (0.70–1.54) / 0.85 / 70/34 / 1.25 / (0.86–1.84) / 0.25 / 69/26 / 1.22 / (0.79–1.89) / 0.38
I / 0–7 / 52/23 / 0.96 / (0.61–1.52) / 0.87 / 52/24 / 0.92 / (0.59–1.44) / 0.72 / 0–9 / 56/29 / 1.14 / (0.72–1.67) / 0.54 / 50/21 / 1.13 / (0.70–1.84) / 0.61
I / 7 / 18/7 / 2.17 / (0.90–5.22) / 0.08 / 18/7 / 1.77 / (0.75–4.20) / 0.19 / 9 / 14/5 / 3.09 / (1.19–8.01) / 0.02 / 19/5 / 1.73 / (0.63–4.75) / 0.28
MHCS / R / 60/32 / 1.00 / – / – / 60/35 / 1.00 / – / – / 78/33 / 1.00 / – / – / 77/27 / 1.00 / – / –
F* / 21/11 / 1.16 / (0.58–2.31) / 0.67 / 21/11 / 1.08 / (0.55–2.13) / 0.82 / 23/7 / 0.74 / (0.33–1.69) / 0.48 / 22/7 / 1.06 / (0.46–2.44) / 0.89
I / 14/10 / 1.72 / (0.84–3.52) / 0.13 / 14/10 / 1.69 / (0.83–3.44) / 0.15 / 15/7 / 1.42 / (0.62–3.24) / 0.41 / 15/7 / 1.74 / (0.75–4.05) / 0.20
I / 0–7 / 7/5 / 1.67 / (0.61–4.60) / 0.32 / 7/5 / 1.54 / (0.56–4.19) / 0.71 / 0–9 / 5/2 / 1.05 / (0.36–3.08) / 0.92 / 4/1 / 0.33 / (0.04–2.51) / 0.29
I / > 7 / 7/5 / 1.75 / (0.66–4.72) / 0.25 / 7/5 / 1.86 / (0.70–4.93) / 0.21 / 9 / 10/5 / 2.46 / (0.69–8.73) / 0.17 / 11/6 / 5.07 / (1.83–14.05) / 0.002
SFCC / R / 45/26 / 1.00 / – / – / 45/27 / 1.00 / – / – / 46/16 / 1.00 / – / – / 46/14 / 1.00 / – / –
F* / 11/7 / 1.01 / (0.44–2.34) / 0.98 / 11/8 / 1.06 / (0.48–2.35) / 0.88 / 12/6 / 1.31 / (0.51–3.35) / 0.58 / 12/6 / 1.52 / (0.58–3.97) / 0.40
I / 13/8 / 1.72 / (0.76–3.88) / 0.19 / 13/8 / 1.51 / (0.68–3.37) / 0.31 / 13/6 / 2.09 / (.81–5.41) / 0.13 / 13/5 / 2.25 / (0.79–6.38) / 0.13
I / 0–7 / 3/1 / 0.60 / (0.07–4.66) / 0.60 / 4/2 / 1.02 / (0.21–4.84) / 0.98 / 0–9 / 6/2 / 1.22 / (0.26–5.77) / 0.81 / 5/1 / 2.68 / (0.24–30.17) / 0.43
I / 7 / 10/7 / 2.31 / (0.95–5.58) / 0.06 / 9/6 / 1.77 / (0.71–4.43) / 0.23 / 9 / 7/4 / 3.08 / (0.96–9.88) / 0.06 / 8/4 / 2.17 / (0.69–6.81) / 0.18
SupplementaryTable 1 Footnotes:
______
a Haplogroup E was excluded because only 35 E seroconverters were available for analysis.
b In the I haplogroup analysis, the times to CD4<2 00 and AIDS-1993 outcomes were divided into two intervals of less than or equal to sevenyears, and greater than seven years. For AIDS-1987 and death, the time intervals were less than or equal to nineyears, and greater than nine years.
c The R haplogroup is the reference group. Relative Hazards results were obtainedafter stratification by cohort. Nine ALIVE cohort samples were excluded from the stratified analysis to maintain power. Their inclusion did not alter the results reported but decreasedtheir significance.
______
______
Supplementary Table 2. Faster progression of Y-I haplogroup subjects to AIDS Outcomes corrected for population stratification and genetic propensity among Cohorts of European-American Seroconverters in Early and Late Time Intervals
CD4 < 200 / AIDS-1993 / AIDS-1987 / DeathHaplo- groupa / Time interval,
yearsb / n/events / RHc / (95% CI) / P / n/events / RHc / (95% CI) / P / Time interval,yearsb / n/events / RHc / (95% CI) / P / n/events / RHc / (95% CI) / P
MACS / R / 249/105 / 1.00 / – / – / 249/116 / 1.00 / – / – / 249/109 / 1.00 / – / – / 244/81 / 1.00 / – / –
F* / 29/9 / 0.85 / (0.42–1.70) / 0.64 / 29/10 / 0.80 / (0.41–1.54) / 0.50 / 30/11 / 0.82 / (0.44–1.56) / 0.55 / 29/6 / 0.64 / (0.27–1.50) / 0.30
I / 66/29 / 1.31 / (0.87–1.99) / 0.20 / 66/30 / 1.23 / (0.82–1.84) / 0.33 / 66/33 / 1.49 / (1.00–2.21) / 0.05 / 65/26 / 1.44 / (0.92–2.25) / 0.11
I / 0–7 / 51/23 / 1.13 / (0.71–1.79) / 0.60 / 51/26 / 1.09 / (0.69–1.70) / 0.71 / 0–9 / 53/27 / 1.26 / (0.82–1.94) / 0.30 / 49/21 / 1.30 / (0.79–2.13) / 0.29
I / > 7 / 15/6 / 3.01 / (1.16–7.85) / 0.02 / 15/6 / 2.40 / (0.94–6.15) / 0.07 / > 9 / 13/6 / 5.52 / (2.06–14.87) / 0.0007d / 16/5 / 2.40 / (0.87–6.65) / 0.09
MHCS / R / 49/27 / 1.00 / – / – / 49/30 / 1.00 / – / – / 63/28 / 1.00 / – / – / 62/23 / 1.00 / – / –
F* / 16/7 / 1.08 / (0.42–2.77) / 0.87 / 16/7 / 0.94 / (0.38–2.31) / 0.88 / 18/5 / 1.05 / (0.38–2.94) / 0.92 / 18/5 / 1.96 / (0.64–5.96) / 0.24
I / 9/6 / 1.93 / (0.74–5.07) / 0.18 / 9/6 / 1.82 / (0.70–4.77) / 0.22 / 9/6 / 1.22 / (0.41–3.61) / 0.71 / 9/4 / 1.20 / (0.36–4.02) / 0.77
I / 0–7 / 5/3 / 0.90 / (0.22–3.58) / 0.88 / 5/3 / 0.83 / (0.21–3.28) / 0.79 / 0–9 / 5/4 / 0.67 / (0.17–2.72) / 0.58 / 4/1 / 0.33 / (0.04–2.51) / 0.29
I / > 7 / 4/3 / 5.57 / (1.41–22.04) / 0.01 / 4/3 / 5.46 / (1.42–20.94) / 0.01 / > 9 / 4/2 / 4.07 / (0.87–18.99) / 0.07 / 6/3 / 2.98 / (0.74–12.05) / 0.13
SFCC / R / 43/25 / 1.00 / – / – / 43/26 / 1.00 / – / – / 44/16 / 1.00 / – / – / 44/14 / 1.00 / – / –
F* / 10/6 / 0.74 / (0.24–2.31) / 0.61 / 10/7 / 0.85 / (0.30–2.44) / 0.76 / 11/5 / 4.13 / (1.11–15.32) / 0.03 / 11/5 / 7.92 / (1.90–33.05) / 0.005
I / 12/8 / 2.01 / (0.86–4.70) / 0.11 / 12/8 / 1.67 / (0.72–3.89) / 0.23 / 12/6 / 2.11 / (0.77–5.81) / 0.15 / 12/5 / 2.27 / (0.76–6.81) / 0.14
I / 0–7 / 3/1 / 0.54 / (0.07–4.44) / 0.57 / 4/2 / 0.94 / (0.20–4.50) / 0.94 / 0–9 / 6/2 / 0.99 / (0.20–4.89) / 0.99 / 5/1 / 2.57 / (0.22–30.17) / 0.45
I / > 7 / 9/7 / 3.02 / (1.19–7.67) / 0.02 / 8/6 / 2.18 / (0.82–5.77) / 0.12 / > 9 / 6/4 / 3.90 / (1.14–13.39) / 0.03 / 7/4 / 2.21 / (0.67–7.35) / 0.19
Supplementary Table 2 Footnotes:
______
a Haplogroup E was excluded because only 35 E seroconverters were available for analysis.
b In the I haplogroup analysis, the times to CD4 <2 00 and AIDS-1993 outcomes were divided into two intervals of less than or equal to seven years, and greater than seven years. For AIDS-1987 and death, the time intervals were less than or equal to nine years, and greater than nine years.
c The R haplogroup is the reference group. Relative Hazards results were obtained after stratification by cohort. Nine ALIVE cohort samples were excluded from the stratified analysis to maintain power. Their inclusion did not alter the results reported but decreased their significance.
dP = 0.0007 corresponds to false-discovery-rate q = 0.031.
______
______
Supplementary Table 3. Haplogroup Distribution of European-American Cases and Controls for HIV Infection and AIDS DefiningIllnesses
Y Chromosome Haplogroups (%)K* / P* / Survival Analyses
Outcomea / n / Y* / B / C / D / E / F* / H / I / (xP) / (xR) / R / Pb / Pc / n/events / RHId / P
Kaposi sarcoma / 342 / 0 / 0 / 0 / 0 / 5.6 / 10.5 / 0 / 18.7 / 3.5 / 0.3 / 61.4 / 0.08 / 0.32 / 439/65e / 2.30 / 0 .007
Lymphoma / 134 / 0 / 0 / 0 / 0 / 6.7 / 10.5 / 0 / 15.7 / 2.2 / 0.8 / 64.2 / 0.85 / 0.93 / 562/22 / 1.21 / 0.73
Total malignancy / 447 / 0 / 0 / 0 / 0 / 5.8 / 10.5 / 0 / 18.8 / 3.1 / 0.5 / 61.3 / 0.09 / 0.26 / 439/79e / 2.00 / 0.009
PCP / 457 / 0.2 / 0.2 / 0 / 0 / 5.7 / 10.3 / 0 / 17.7 / 1.5 / 0.7 / 63.7 / 0.87 / 0.50 / 562/100 / 1.26 / 0.36
CMV virus / 288 / 0.4 / 0 / 0 / 0 / 6.9 / 8.7 / 0 / 18.1 / 3.8 / 0.4 / 61.8 / 0.04 / 0.43 / 562/59 / 1.04 / 0.91
MAC / 258 / 0 / 0 / 0 / 0 / 5.8 / 11.6 / 0 / 19.4 / 1.9 / 0 / 61.2 / 0.57 / 0.25 / 562/42 / 1.84 / 0.10
Other OI / 427 / 0 / 0.2 / 0 / 0 / 6.3 / 8.7 / 0.2 / 19.4 / 2.6 / 0.7 / 62.0 / 0.14 / 0.16 / 562/96 / 0.63 / 0.15
Total OI / 874 / 0.2 / 0.1 / 0 / 0 / 6.5 / 10.3 / 0.1 / 18.2 / 2.2 / 0.8 / 61.6 / 0.26 / 0.27 / 562/198 / 1.09 / 0.66
Patient subgroupf
LTNP / 76 / 0 / 0 / 0 / 0 / 2.6 / 17.1 / 0 / 14.5 / 4.0 / 1.3 / 60.5 / 0.14 / 0.61
HREU / 154 / 0 / 0 / 0 / 0 / 9.2 / 13.7 / 0 / 19.6 / 2.6 / 0 / 54.9 / 0.11 / 0.25
Seroconverters / 606 / 0 / 0 / 0 / 0.2 / 5.8 / 11.0 / 0 / 16.1 / 1.0 / 0.3 / 65.6
Supplementary Table 3 Footnotes:
______
a PCP: pneumocystis carinii pneumonia; CMV: cytomegalovirus; MAC: mycobacterium avium complex; OI: opportunistic
infection; Other OI: candidiasis, cryptococcosis, coccidioidomycosis, histoplasmosis, cryptosporidiosis, isosporiasis,
toxoplasmosis, herpes simplex, progressive multifocal leukoencephalopathy, various bacterial infections; Total OI: includes
PCP, CMV virus, MAC, and other OI; Total malignancy includes Kaposi sarcoma and lymphoma.
b Frequency of combined Y*BCDE, F*,H, I, KLMNO, and K*(xP)P*(xR)R haplogroups in each disease group compared to those in a
control group of seroconverters.
c Frequency of haplogroup I in each disease group compared to other haplogroups in the seroconverter control group.
d Relative hazard estimates for haplogroup I using haplogroup R as the reference.
e Results using only MACS and SFCC cohort samples. Kaposi sarcoma was seen only in men who have sex with men. The
significance of the KS results derives primarily from the SFCC cohort (n/events = 71/16, RH = 5.51, and P = 0.005), while the
MACS only trend in the same direction (n/events = 368/49, RH = 1.70, and P = 0.12). The related total malignancy analysis include
Kaposi sarcoma and the significance of the results also derived primarily from SFCC (n/events = 71/20, RH = 3.11, and P = 0.03).
f LTNP: Long-Term Non-progressors. (Seroconverters who have been in the study for 15 years or more and have remained disease free); HREU: High-risk exposed uninfected individuals.
______
Supplementary Table 4. Faster Progression of Y-I haplogroup subjects to AIDS Outcomes Including Genetic Propensity Indexa Values among Cohorts of European- American Seroconverters
CD4 < 200 / AIDS-1993 / AIDS-1987 / DeathHaplo- groupb / Time interval,
yearsc / n/events / RHd / (95% CI) / P / n/events / RHd / (95% CI) / P / Time interval,
yearsc / n/events / RHd / (95% CI) / P / n/events / RHd / (95% CI) / P
MACS / R / 267/114 / 1.00 / – / – / 267/125 / 1.00 / – / – / 267/120 / 1.00 / – / – / 262/89 / 1.00 / – / –
F* / 30/10 / 0.79 / (0.41–1.51) / 0.48 / 30/11 / 0.77 / (0.42–1.43) / 0.41 / 31/11 / 0.76 / (0.41–1.41) / 0.38 / 30/6 / 0.60 / (0.26–1.36) / 0.22
I / 70/30 / 1.13 / (0.76–1.69) / 0.55 / 70/31 / 1.07 / (0.72–1.59) / 0.73 / 70/34 / 1.34 / (0.91–1.96) / 0.14 / 69/26 / 1.28 / (0.83–1.98) / 0.27
I / 0–7 / 52/23 / 0.98 / (0.62–1.55) / 0.94 / 52/24 / 0.95 / (0.61–1.48) / 0.83 / 0–9 / 56/29 / 1.16 / (0.76–1.76) / 0.49 / 50/21 / 1.18 / (0.73–1.91) / 0.51
I / > 7 / 18/7 / 2.18 / (0.91–5.23) / 0.08 / 18/7 / 1.85 / (0.78–4.37) / 0.16 / >9 / 14/5 / 3.78 / (1.44–9.88) / 0.007 / 19/5 / 1.94 / (0.71–5.32) / 0.20
Propensity Index / 1.88 / (1.42–2.50) / <0.0001 / 1.64 / (1.32–2.05) / <0.0001 / 1.56 / (1.26–1.93) / <0.0001 / 2.04 / (1.46–2.86) / <0.0001
MHCS / R / 60/32 / 1.00 / – / – / 60/35 / 1.00 / – / – / 78/33 / 1.00 / – / – / 77/27 / 1.00 / – / –
F* / 21/11 / 1.13 / (0.57–2.25) / 0.73 / 21/11 / 1.04 / (0.53–2.05) / 0.91 / 23/7 / .69 / (0.31–1.57) / 0.38 / 22/7 / 1.10 / (0.47–2.55) / 0.83
I / 14/10 / 2.37 / (1.13–4.99) / 0.02 / 14/10 / 2.23 / (1.07–4.66) / 0.03 / 15/7 / 1.39 / (0.60–3.23) / 0.45 / 15/7 / 1.71 / (0.72–4.05) / 0.22
I / 0–7 / 7/5 / 1.53 / (0.55–4.21) / 0.41 / 7/5 / 1.37 / (0.50–3.76) / 0.54 / 0–9 / 5/2 / .84 / (0.28–2.50) / 0.75 / 4/1 / 0.28 / (0.04–2.17) / 0.22
I / > 7 / 7/5 / 4.40 / (1.52–12.72)) / 0.006 / 7/5 / 4.48 / (1.55–12.91) / 0.005 / >9 / 10/5 / 4.30 / (1.18–15.75) / 0.03 / 11/6 / 6.30 / (2.18–18.21) / 0.0007 / e
Propensity Index / 3.20 / (1.98–5.17) / <0.0001 / 2.47 / (1.69–3.60) / <0.0001 / 2.22 / (1.48–3.34) / 0.0001 / 2.67 / (1.53–4.66) / 0.0005
SFCC / R / 45/26 / 1.00 / – / – / 45/27 / 1.00 / – / – / 46/16 / 1.00 / – / – / 46/14 / 1.00 / – / –
F* / 11/7 / 0.99 / (0.43–2.29) / 0.98 / 11/8 / 1.01 / (0.46–2.23) / 0.98 / 12/6 / 1.28 / (0.50–3.27) / 0.61 / 12/6 / 1.55 / (0.59–4.07) / 0.37
I / 13/8 / 1.70 / (0.74–3.88) / 0.21 / 13/8 / 1.43 / (0.63–3.25) / 0.39 / 13/6 / 1.96 / (0.75–5.18) / 0.17 / 13/5 / 2.38 / (0.83–6.82) / 0.11
I / 0–7 / 3/1 / 0.53 / (0.07–4.37) / 0.56 / 4/2 / 0.92 / (0.19–4.42) / 0.92 / 0–9 / 6/2 / 1.06 / (0.22–5.10) / 0.94 / 5/1 / 2.56 / (0.23–28.91) / 0.45
I / > 7 / 10/7 / 2.35 / (0.96–5.76) / 0.06 / 9/6 / 1.72 / (0.67–4.34) / 0.26 / >9 / 7/4 / 3.10 / (0.94–10.15) / 0.06 / 8/4 / 2.34 / (0.74–7.43) / 0.15
Propensity Index / 2.36 / (1.34–4.18) / 0.003 / 2.12 / (1.35–3.36) / 0.001 / 2.04 / (1.21–3.43) / 0.008 / 2.06 / (0.99–4.28) / 0.05
Supplementary Table 4 Footnotes:
______
a Calculated as in O’Brien and Nelson (2004).
b Haplogroup E was excluded because only 35 E seroconverters were available for analysis.
c In the I haplogroup analysis, the times to CD4 < 200 and AIDS-1993 outcomes were divided into two intervals of less than or equal to seven years, and greater than seven years. For AIDS-1987 and death, the time intervals were less than or equal to nine years, and greater than nine years.
d The R haplogroup is the reference group. Relative Hazards results were after stratification by cohort. Nine ALIVE cohort samples were excluded from the stratified analysis to maintain power. Their inclusion did not alter the results reported but decreased their significance.
eP = 0.0007 corresponds to false-discovery-rateq = 0.031.
______
______
Supplementary Table 5. Mean Virus (HIV-1) RNA Load among
European-American Seroconverters
Haplogroupa / n / Mean VLb / SD / Ln Mean VLc / SDR / 276 / 71,507 / 123,904 / 9.86 / 1.64
I / 72 / 86,690 / 151,196 / 10.06 / 1.76
F* / 33 / 70,030 / 157,693 / 9.86 / 1.59
a Other haplogroups, which had fewer seroconverters, were excluded from
the analysis.
b ANOVA of mean viral load (VL) across the three haplogroups P = 0.66.
c ANOVA of log-mean viral load across the three haplogroups P = 0.68.
ANOVA of log-mean viral load Y-I haplogroup versus the other two
combined haplogroups P = 0.36.
______
______
Supplementary Table 6. Progression to AIDS Outcomes among African-American Seroconverters
CD4 < 200 / AIDS 1993 / AIDS 1987 / DeathHaplo- groupa / n/events / RHb / (95% CI) / P / n/events / RHb / (95% CI) / P / n/events / RHb / (95% CI) / P / n/events / RHb / (95% CI) / P
African / E / 146/35 / 1.00 / – / – / 146/39 / 1.00 / – / – / 169/24 / 1.00 / – / – / 167/12 / 1.00 / – / –
Americans / R / 35/8 / 0.67 / (0.31–1.47) / 0.32 / 35/9 / 0.70 / (0.34–1.46) / 0.34 / 36/3 / 0.52 / (0.16–1.72) / 0.28 / 35/1 / 0.32 / (0.04–2.50) / 0.28
I / 5/1 / 0.49 / (0.07–3.61) / 0.48 / 5/1 / 0.45 / (0.06–3.29) / 0.43 / 6/0 / –c / ( – ) / 0.18 / 6/0 / – c / ( – ) / 0.16
ALIVE / E / 110/28 / 1.00 / – / – / 110/30 / 1.00 / – / – / 132/13 / 1.00 / – / – / 132/6 / 1.00 / – / –
R / 23/6 / 0.90 / (0.37–2.20) / 0.82 / 23/6 / 0.88 / (0.36–2.86) / 0.77 / 24/1 / 0.38 / (0.05–2.94) / 0.36 / 24/0 / – d / ( – ) / 0.15
I / 4/1 / 0.39 / (0.05–2.92) / 0.36 / 4/1 / 0.39 / (0.05–2.86) / 0.35 / 5/0 / – c / ( – ) / 0.16 / 5/0 / – c / ( – ) / 0.33
a Other haplogroups, which had fewer seroconverters, were excluded from the analysis.
b The E haplogroup is the reference group. Relative hazards results were obtained without stratification because cohorts
other than ALIVE contributed many fewer samples and events.
c The I haplogroup had no failures. P values from exact calculation of Log-likelihood χ2 difference from the
two Cox models.
d The R haplogroup had no failures. P values from exact calculation of log-likelihood χ2 difference from the
two Cox models.
______
______
Supplementary Table 7. Progression to AIDS Outcomes Including Genetic Propensity Indexa Values among African-American Seroconverters
CD4 < 200 / AIDS 1993 / AIDS 1987 / DeathHaplo- group / n/events / RHb / (95% CI) / P / n/events / RHb / (95% CI) / P / n/events / RHb / (95% CI) / P / n/events / RHb / (95% CI) / P
African / E / 146/35 / 1.00 / – / – / 146/39 / 1.00 / – / – / 169/24 / 1.00 / – / – / 167/12 / 1.00 / – / –
Americans / R / 35/8 / 0.72 / (0.33–1.57) / 0.41 / 35/9 / 0.53 / (0.38–1.65) / 0.53 / 36/3 / 0.62 / (0.19–2.06) / 0.43 / 35/1 / 0.39 / (0.05–2.99) / 0.36
I / 5/1 / 1.11 / (0.14–8.64) / 0.92 / 5/1 / 0.93 / (0.12–6.97) / 0.93 / 6/0 / –c / ( – ) / 0.18 / 6/0 / – c / ( – ) / 0.52
Propensity Index / 3.01 / (1.64–5.52) / 0.0004 / 3.13 / (1.57–6.24) / 0.001 / 2.20 / (1.16–4.17) / 0.02 / 1.33 / (0.74–2.41) / 0.34
ALIVE / E / 110/28 / 1.00 / – / – / 110/30 / 1.00 / – / – / 132/13 / 1.00 / – / – / 132/6 / 1.00 / – / –
R / 23/6 / 0.85 / (0.35–2.07) / 0.71 / 23/6 / 0.86 / (0.36–2.09) / 0.74 / 24/1 / 0.38 / (0.05–2.93) / 0.36 / 24/0 / – d / ( – ) / 0.15
I / 4/1 / 0.87 / (0.10–6.78) / 0.87 / 4/1 / 0.73 / (0.09–5.72) / 0.76 / 5/0 / – c / ( – ) / 0.22 / 5/0 / – c / ( – ) / 0.33
Propensity Index / 2.65 / (1.34–5.22) / 0.005 / 2.63 / (1.24–5.57) / 0.01 / 1.87 / (0.86–4.06) / 0.11 / 1.23 / (0.71–2.15) / 0.46
a Calculated as in O’Brien and Nelson (2004).
b The E haplogroup is the reference group. Relative hazards results were obtained without stratification because cohorts
other than ALIVE contributed many fewer samples and events.
c The I haplogroup had no failures. P values from exact calculation of log-likelihood χ2 difference from the
two Cox models.
d The R haplogroup had no failures. P values from exact calculation of log-likelihood χ2 difference from the
two Cox models.
______
______
Supplementary Table 8. Progression to AIDS Outcomes Including Population Stratification and Genetic Propensity Indexa Values among African-American Seroconverters
CD4 < 200 / AIDS 1993 / AIDS 1987 / DeathHaplo- group / n/events / RHb / (95% CI) / P / n/events / RHb / (95% CI) / P / n/events / RHb / (95% CI) / P / n/events / RHb / (95% CI) / P
African / E / 141/34 / 1.00 / – / – / 141/38 / 1.00 / – / – / 162/25 / 1.00 / – / – / 160/13 / 1.00 / – / –
Americans / R / 33/8 / 0.68 / (0.29–1.61) / 0.38 / 33/8 / 0.70 / (0.31–1.61) / 0.40 / 34/2 / 0.38 / (0.08–1.73) / 0.21 / 34/1 / 0.40 / (0.04–4.46) / 0.46
I / 5/1 / 1.06 / (0.13–8.58) / 0.92 / 5/1 / 0.90 / (0.11–7.10) / 0.92 / 6/0 / –c / ( – ) / 0.90 / 6/0 / – c / ( – ) / 0.76
Propensity Index / 3.67 / (1.92–7.00) / 0.0001 / 4.16 / (1.96–8.85) / 0.0002 / 2.97 / (1.38–6.36) / 0.005 / 1.34 / (0.73–2.47) / 0.35
ALIVE / E / 105/27 / 1.00 / – / – / 105/29 / 1.00 / – / – / 125/14 / 1.00 / – / – / 125/7 / 1.00 / – / –
R / 23/6 / 0.61 / (0.22–1.71) / 0.35 / 23/6 / 0.64 / (0.24–1.73) / 0.38 / 24/1 / 0.17 / (0.02–1.60) / 0.12 / 24/0 / – d / ( – ) / 0.75
I / 4/1 / 0.96 / (0.11–8.42) / 0.98 / 4/1 / 0.76 / (0.09–6.42) / 0.80 / 5/0 / – c / ( – ) / 0.92 / 5/0 / – c / ( – ) / 0.75
Propensity Index / 2.65 / (1.34–5.22) / 0.005 / 4.12 / (1.76–9.68) / 0.001 / 3.01 / (1.07–8.46) / 0.04 / 1.31 / (0.59–2.89) / 0.51
a Calculated as in O’Brien and Nelson (2004).
b The E haplogroup is the reference group. Relative hazards results were obtained without stratification because cohorts
other than ALIVE contributed many fewer samples and events.
c The I haplogroup had no failures. P values from exact calculation of log-likelihood χ2 difference from the
two Cox models.
d The R haplogroup had no failures. P values from exact calculation of log-likelihood χ2 difference from the
two Cox models.
______
S1